Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of PGT-A Versus PGT-A+ERA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Majority of age patients whose written informed consent approved by the Ethics Committee (EC) has been obtained, after having been duly informed of the nature of the study and voluntarily accepted to participate after being fully aware of the potential risks, benefits and any discomfort involved.~* Patients who already have frozen euploid blastocysts (day 5/6 development) analysed by PGT-A.~* Patients with embryos obtained from their own oocytes fertilized by Intracytoplasmic Sperm Injection (ICSI) or In vitro fertilization (IVF).~* Patients with an expected embryo transfer of one or two embryos (Single ET or Double ET) in a HRT cycle.~* Body Mass Index: 18,5-30 Kg/m2.~Exclusion Criteria:~* Presence of pathologies or malformations that affect the uterine cavity such as polyps, intramural myomas ≥ 4cm or submucosal, septum or hydrosalpinx during the patient's participation in the study. Patients suffering these pathologies before or after their inclusion in the study are allowed to participate if the pathology is corrected before performing any study procedure.~* Any illness or medical condition that is unstable or which, according to medical criteria, may put at risk the patient's safety and her compliance in the study.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PGT-A without ERA (Type: OTHER): Patients with PGT-A indication and ET in a Hormone Replacement Therapy (HRT cycle) according to the usual clinical practice (day 5 of progesterone supplementation: P+5/120h).
- PGT-A and test ERA (Type: OTHER): Patients with PGT-A indication and pET in HRT cycle following the ERA test indication (when the WOI is confirmed as Receptive).

Based on this trial design, predict the completion outcome and termination type (if applicable).